Literature DB >> 17982093

Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo.

Hatice Hasturk1, Alpdogan Kantarci, Emilie Goguet-Surmenian, Amanda Blackwood, Chris Andry, Charles N Serhan, Thomas E Van Dyke.   

Abstract

Resolvin E1 (RvE1) is a potent proresolving mediator of inflammation derived from omega-3 eicosapentaenoic acid that acts locally to stop leukocyte recruitment and promote resolution. RvE1 displays potent counter-regulatory and tissue-protective actions in vitro and in vivo. Periodontal disease is a local inflammatory disease initiated by bacteria characterized by neutrophil-mediated tissue injury followed by development of a chronic immune lesion. In this study, we report the treatment of established periodontitis using RvE1 as a monotherapy in rabbits compared with structurally related lipids PGE(2) and leukotriene B(4). PGE(2) and leukotriene B(4) each enhanced development of periodontitis and worsened the severity of disease. Promotion of resolution of inflammation as a therapeutic target with RvE1 resulted in complete restoration of the local lesion, and reduction in the systemic inflammatory markers C-reactive protein and IL-1beta. This report is the first to show that resolution of inflammation by a naturally occurring endogenous lipid mediator results in complete regeneration of pathologically lost tissues, including bone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982093     DOI: 10.4049/jimmunol.179.10.7021

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  181 in total

Review 1.  Paradigm shift in the pharmacological management of periodontal diseases.

Authors:  Hatice Hasturk; Alpdogan Kantarci; Thomas E Van Dyke
Journal:  Front Oral Biol       Date:  2011-11-11

2.  Dependence of resolvin-induced increases in corneal epithelial cell migration on EGF receptor transactivation.

Authors:  Fan Zhang; Hua Yang; Zan Pan; Zheng Wang; J Mario Wolosin; Per Gjorstrup; Peter S Reinach
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 3.  Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators.

Authors:  Eric L Campbell; Charles N Serhan; Sean P Colgan
Journal:  J Immunol       Date:  2011-10-01       Impact factor: 5.422

Review 4.  Activation and resolution of periodontal inflammation and its systemic impact.

Authors:  Hatice Hasturk; Alpdogan Kantarci
Journal:  Periodontol 2000       Date:  2015-10       Impact factor: 7.589

5.  Developments of specialized pro-resolving mediators in periodontitis.

Authors:  Yin-Chen Liu
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-02-01

6.  Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1.

Authors:  Naveen K Rajasagi; Pradeep B J Reddy; Amol Suryawanshi; Sachin Mulik; Per Gjorstrup; Barry T Rouse
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

7.  n-3 fatty acids and periodontitis in US adults.

Authors:  Asghar Z Naqvi; Catherine Buettner; Russell S Phillips; Roger B Davis; Kenneth J Mukamal
Journal:  J Am Diet Assoc       Date:  2010-11

8.  Testosterone regulates bone response to inflammation.

Authors:  J P Steffens; B S Herrera; L S Coimbra; D N Stephens; C Rossa; L C Spolidorio; A Kantarci; T E Van Dyke
Journal:  Horm Metab Res       Date:  2014-02-13       Impact factor: 2.936

9.  Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes.

Authors:  Bruno S Herrera; Hatice Hasturk; Alpdogan Kantarci; Marcelo O Freire; Olivia Nguyen; Shevali Kansal; Thomas E Van Dyke
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

10.  The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury.

Authors:  Hiroyuki Seki; Koichi Fukunaga; Makoto Arita; Hiroyuki Arai; Hiroki Nakanishi; Ryo Taguchi; Taku Miyasho; Rina Takamiya; Koichiro Asano; Akitoshi Ishizaka; Junzo Takeda; Bruce D Levy
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.